Skip to main content

Keros Therapeutics, Inc. (KROS)

NASDAQ: KROS · IEX Real-Time Price · USD
56.10 -2.45 (-4.18%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap1.31B
Revenue (ttm)100,000
Net Income (ttm)-61.47M
Shares Out23.40M
EPS (ttm)-2.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume220,331
Open60.87
Previous Close58.55
Day's Range55.30 - 59.00
52-Week Range28.50 - 88.80
Betan/a
AnalystsBuy
Price Target86.25 (+53.7%)
Earnings DateNov 8, 2021

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also develop...

IndustryBiotechnology
IPO DateApr 8, 2020
Employees45
Stock ExchangeNASDAQ
Ticker SymbolKROS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is 86.25, which is an increase of 53.74% from the latest price.

Price Target
$86.25
(53.74% upside)
Analyst Consensus: Buy

News

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

3 weeks ago - GlobeNewsWire

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Pre...

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

3 weeks ago - GlobeNewsWire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associate...

LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 month ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

3 months ago - GlobeNewsWire

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

3 months ago - GlobeNewsWire

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with ...

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

5 months ago - GlobeNewsWire

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati...

6 months ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an...

6 months ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

8 months ago - GlobeNewsWire

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of...

LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

8 months ago - GlobeNewsWire

Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

9 months ago - GlobeNewsWire

Last Week's Notable Insider Buys: Avis, Biglari And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

1 year ago - Benzinga

Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...

LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

1 year ago - GlobeNewsWire

Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplast...

LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

1 year ago - GlobeNewsWire

U.S. IPO Week Ahead: The IPO Market Cools Off In A 2-IPO Week

Following an active September, two IPOs are scheduled to raise $200 million in the week ahead.

Other symbols:FUBO
1 year ago - Seeking Alpha

Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerciali...

1 year ago - GlobeNewsWire

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone a...

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

1 year ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

1 year ago - GlobeNewsWire

Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series

LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...

1 year ago - GlobeNewsWire

Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Prog...

LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...

1 year ago - GlobeNewsWire

Keros Therapeutics Set to Join Russell 2000® Index

LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

1 year ago - GlobeNewsWire